Clinical Significance of Vitamin D Deficiency in Primary Hyperparathyroidism, and Safety of Vitamin D Therapy

Table.  Overview of studies of vitamin D supplementation in patients with concomitant vitamin D deficiency and primary hyperparathyroidism ^a

	Grey et al24	Tucci25	Isidro and Ruano26	Grubbs et al27	Kantorovich et al15
Design	Prospective audit study	Prospective audit study	Prospective	Retrospective, controlled	Retrospective
Follow-up	12 mo	34 wk	12 mo	6 mo	12 mo
Patient number and gender	n = 25, 23 women	n = 56, 37 women	n = 27, 24 women	n = 112, 87 women	n = 5, gender not reported
Mean age (yr)	68	30	67	58	Not reported
Regimen of vitamin D therapy	Cholecalciferol (vitamin D3) 50,000 IU/wk for 1 mo, then 50,000 IU/mo for 12 mo	Ergocalciferol (vitamin D2) 50,000 U/wk for 8 wk, followed by 800 U/day up to 100,000 U/mo to keep serum vitamin D ≥75 mmol/L (30 ng/mL)	Calcifediol (25OH vitamin D) 480–960 IU/d	Ergocalciferol (vitamin D2) 50,000 units two to three times/wk for four to 8 wk to keep serum vitamin D ≥75 mmol/L (30 ng/mL)	Vitamin D2 50,000 U + 1000 mg elemental calcium twice/wk for 5 wk
Mean serum levels of 25-OHD at baseline	11 ng/mL	14 ng/mL	11 ng/mL	18 ng/mL	8 ng/mL
Mean serum levels of 25-OHD after vitamin D therapy	31 ng/mL after one year	37 ng/mL after 34 wk	28 ng/mL after 12 mo	46 ng/mL after four to 8 wk	20 ng/ml after 5 wk
Mean serum levels of calcium at baseline	10.8 mg/dL	11 mg/dL	10.8 mg/dL	10.9 mg/dL	10.1 mg/dL
Mean serum levels of calcium after vitamin D therapy	10.8 mg/dL	10.8 mg/dL	10.9 mg/dL	10.7 mg/dL	10.1 mg/dL
Patients having increase in serum calcium levels	Calcium increased in one patient from 10.5 to 11.3 mg/dL	Calcium increased in two patients from 11.2 to 12.1 mg/dL, and from 11.3 to 12.2 mg/dL at 10 wk	Calcium increased in two patients from 10.8 to 12.4 mg/dL, and from 10.8 to 12 mg/dL. Vitamin D therapy was discontinued in the two patients after 3 mo	Calcium increased in six of 112 patients (5%) to a maximum levels of 11.7 mg/dL	Calcium increased in one patient from 10.5 to 10.9 mg/dL
Baseline mean serum levels of intact PTH	138 pg/mL	144 pg/mL	188 pg/mL	175 pg/mL	107 pg/mL
Serum levels of PTH after vitamin D therapy	102 pg/mL (26% significant reduction, P < 0.004)	133 pg/mL after (7% reduction, not statistically significant)	162 pg/mL (14% reduction, not statistically significant)	164 pg/mL (6% significant reduction, P < 0.01)	104 pg/mL (3% reduction, not Statistically significant)
Change in urine calcium after vitamin D therapy	Two patients had urine calcium >400 mg/24 hr	No significant change	Significant increase in the mean value from 228 to 316 mg/24 hr	Not reported	Significant increase in mean urinary calcium/creatinine ratio from 0.06 to 0.24. Three of the five patients developed hypercalciuria (urinary calcium/creatinine ratio >0.160)

^a25-OHD, 25-hydroxy vitamin D; PTH, parathyroid hormone.

Authors and Disclosures

Nasser Mikhail, MD, MSc

Division of Endocrinology, Olive-View-UCLA Medical Center, Sylmar, CA.

Reprint requests to
Nasser Mikhail, MD, MSc, Division of Endocrinology, Department of Medicine, Olive View-UCLA Medical Center, Sylmar, CA 91342. Email: nmikhail@dhs.lacounty.gov

Sidebar

Key Points

• Vitamin D inadequacy is more common in patients with primary hyperparathyroidism than in the general population.

• Hypovitaminosis D is generally associated with an aggravated biochemical profile of primary hyperparathyroidism.

• Initiation of vitamin D therapy is recommended in patients with serum levels of 25-hydroxy vitamin D <20 ng/mL and concomitant hyperparathyroidism.

• Well-designed trials are needed to better define the safety and efficacy of vitamin D therapy in patients with concomitant vitamin D deficiency and primary hyperparathyroidism.